Vendor comparison · 2026
Tesamorelin vendors: 31 compared on COAs and price
MetabolicAlso known as Egrifta, TH9507
Evidence tier
Regulator-reviewed human evidence
2 human trials · 1 review · 1 observational
- Vendors carrying it
- 31
- 27 with a listed price
- Vendors with checkable COAs
- 15
- 17 publish any certificate
- Lots tested
- 33
- 31 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 18 Sept 2026
- oldest 24 Dec 2025
- Laboratories named
- 10
- most often Freedom Diagnostics Testing
- Median label gap
- 6.5%
- 48% of lots within 5% of label
- Median purity
- 99.71%
- 33 of 33 lots at 99% or above
- Lowest price per mg
- $4.00
- peer median $8.00
- Publications located
- 120
- researched since 2003
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable Tesamorelin testing in this index: 7 lots assayed by ILS Laboratories, the newest on 14 Sept 2026. The lowest listed price is $4.00 per mg at Good Science Bio, against a peer median of $8.00. 31 vendors carrying Tesamorelin are compared below. 15 publish at least one certificate naming a checkable laboratory, 33 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Tesamorelin
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 2 / 2 | Freedom Diagnostics Testing | 99.8% | 18.2% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $5.00 (63%) | 7 / 7 | ILS Laboratories | 99.5% | 4.6% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 90.694% | $6.30 (79%) | 3 / 3 | Kovera Labs, Kovera Labs and/or ILS Labs | 99.6% | 2.6% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 8898% | $7.00 (88%) | 0 | — | — | — | — | |
| 5 | PeptidePlugs | 86.894% | $7.00 (88%) | 3 / 3 | Freedom Diagnostics Testing | 99.9% | 10.1% | ||
| 6 | One Aminos | 84.389% | $7.00 (88%) | 1 / 1 | United Laboratories | 99.8% | 4.3% | ||
| 7 | Modern AminosISO/IEC 17025COAs need an account | 83.197% | $7.10 (89%) | 2 / 2 | Freedom Diagnostics Testing | 99.8% | 9.6% | ||
| 8 | CuroISO/IEC 17025 | 82.897% | $8.45 (106%) | 1 / 1 | BTLabs | 99.8% | 23.0% | ||
| 9 | Northline LabsISO/IEC 17025 | 81.595% | $8.00 (100%) | 2 / 2 | ILS Laboratories, Horizon Analytical | 99.3% | 2.1% | ||
| 10 | Simple Peptide | 80.392% | $7.50 (94%) | 2 / 2 | Freedom Diagnostics Testing | 99.7% | 45.5% | ||
| 11 | NeuroLabs Research | 7791% | $9.50 (119%) | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 33.0% | ||
| 12 | Protide HealthAge-gated COAs | 76.892% | $8.50 (106%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Ascension Peptides | 76.489% | $10.00 (125%) | 1 / 1 | MZ Biolabs | 99.9% | 16.6% | ||
| 14 | Prime PeptidesISO/IEC 17025 | 75.796% | $8.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Evo Labs Research | 74.887% | $7.00 (88%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Good Science Bio | 74.571% | $4.00 (50%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Koi PeptidesAge-gated COAs | 73.992% | $9.00 (113%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Bench Grade Peptides | 71.289% | $11.80 (148%) | 3 / 3 | AV Analytics, Freedom Diagnostics Testing | 99.8% | 6.1% | ||
| 19 | Eternal Peptides | 67.563% | $5.80 (73%) | 0 | — | — | — | — | no reportVisit site |
| 20 | True Research Labs | 66.768% | $6.90 (86%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Biotech Peptides | 63.860% | $7.30 (91%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Disguised Alpha | 62.766% | $8.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Licensed Peptides | 60.887% | $13.10 (164%) | 1 / 1 | Vanguard Laboratory | 99.0% | 14.0% | ||
| 24 | Mile High Compounds | 60.591% | $8.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 25 | BioLongevity Labs | 60.172% | $10.94 (137%) | 0 | — | — | — | — | no reportVisit site |
| 26 | Extreme Peptides | 57.980% | — | 0 / 1 | Not named | 99.6% | 0.0% | ||
| 27 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 16.0% | ||
| 28 | GenX Peptides | 55.869% | $12.00 (150%) | 0 | — | — | — | — | no reportVisit site |
| 29 | Peptime | 55.557% | — | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 13.9% | ||
| 30 | Improved Peptides | 54.187% | $15.00 (188%) | 0 / 1 | Not named | 99.7% | 75.4% | ||
| 31 | Sports Technology LabsAge-gated COAs | 50.771% | $17.00 (213%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Tesamorelin is on file. All 33 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
33 of 33 lots at 99% or above; median 99.71%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 7 |
| ≥99.5% | 26 |
48% of lots within 5% of the labelled mass; median gap 6.5%.
| Range | lots |
|---|---|
| ≤2% | 6 |
| 2–5% | 10 |
| 5–10% | 3 |
| 10–20% | 9 |
| >20% | 5 |
27 vendors, $4.00 to $17.00; median $8.00.
| Range | vendors |
|---|---|
| $0–$5.00 | 1 |
| $5.00–$10.00 | 19 |
| $10.00–$15.00 | 5 |
| $15.00–$20.00 | 2 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 13 | 8 | 39% | Public lookup |
| ILS LaboratoriesUS | 8 | 2 | 24% | Public lookup |
| AV Analytics | 2 | 1 | 6% | No public lookup found |
| Kovera Labs | 2 | 1 | 6% | No public lookup found |
| BTLabs | 1 | 1 | 3% | No public lookup found |
| Horizon Analytical | 1 | 1 | 3% | No public lookup found |
| Kovera Labs and/or ILS Labs | 1 | 1 | 3% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 3% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 3% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 3% | No public lookup found |
2 further records nameno checkable laboratory (a placeholder, a signature line or the vendor’s own name). They are listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2003 — 23 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
120 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 33 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.21 pts purity across lots, mean label deviation 13.2%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
31 of 31 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
31 of 33 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Tesamorelin?
A stabilised analogue of growth-hormone-releasing hormone, approved to reduce excess visceral abdominal fat in a specific clinical population.
Studied in published research for reducing visceral abdominal fat and growth-hormone release.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Approved as a medicine (Egrifta) and studied in human trials of visceral fat reduction. PepIndex does not evaluate clinical significance and does not describe administration.
- Tesamorelin — PubMed (2012)
Peer-reviewed article indexed in PubMed, published in PubMed (2012).
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors — AIDS (London, England) (2024)
Peer-reviewed article indexed in PubMed, published in AIDS (London, England) (2024).
- Tesamorelin — Nature reviews. Drug discovery (2011)
Peer-reviewed article indexed in PubMed, published in Nature reviews. Drug discovery (2011).
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — The Annals of pharmacotherapy (2012)
Peer-reviewed article indexed in PubMed, published in The Annals of pharmacotherapy (2012).
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs (2011)
Peer-reviewed article indexed in PubMed, published in Drugs (2011).
- Tesamorelin update — BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation (2010)
Peer-reviewed article indexed in PubMed, published in BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation (2010).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Tesamorelin, a human growth hormone releasing factor analogue — Expert opinion on investigational drugs (2009)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2009).
Indexed studies4 human-evidence of 4
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors — Human — controlled trial, 2024
Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo amon…
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials — Meta-analysis, 2026
HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorel…
- Approach to the Patient With Lipodystrophy — Case report, 2022
Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, sugg…
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity — Human — controlled trial, 2025
In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. This 6-month phase 2 randomized open-label clinical trial compared tesam…
Evidence digest
What the research on Tesamorelin actually shows
The indexed literature on Tesamorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tesamorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.